Đang chuẩn bị liên kết để tải về tài liệu:
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologicallyselected advanced colorectal cancer patients: The CIFRA study protocol

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC). | Cetuximab irinotecan and fluorouracile in fiRst-line treatment of immunologicallyselected advanced colorectal cancer patients The CIFRA study protocol

TÀI LIỆU LIÊN QUAN

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Dose escalating study of cetuximab and 5-FU/ folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologicallyselected advanced colorectal cancer patients: The CIFRA study protocol